Rare levetiracetam-related adverse events in treatment of epilepsy
https://doi.org/10.17749/2077-8333/epi.par.con.2026.258
Abstract
The article systematizes data on rare levetiracetam-related adverse events that go beyond the approved data provided in package insert. The key factor in selecting an antiepileptic drug is the risk-benefit ratio, which is largely determined by the knowledge of all potential adverse effects. This review aims to increase awareness of adverse reactions to levetiracetam in patients with epilepsy. Further research is needed to explore the pathogenetic mechanisms and identify risk factors of adverse effects for better understanding of the drug safety profile.
About the Authors
T. V. Melashenko
Children's Clinical Hospital No. 22
Russian Federation
Russian Federation
Tatiana V. Melashenko - PhD.
1 Zavodskoy Ave., Kolpino, Saint Petersburg 196657
Z. G. Tadtaeva
Saint Petersburg Pediatric Medical University
Russian Federation
Russian Federation
Zara G. Tadtaeva - Dr. Sci. Med., Prof.
2 Litovskaya Str., Saint Petersburg 194100
A. N. Galustyan
Saint Petersburg Pediatric Medical University
Russian Federation
Russian Federation
Anna N. Galustyan - PhD, Assoc. Prof.
2 Litovskaya Str., Saint Petersburg 194100
N. A. Galankin
Saint Petersburg Pediatric Medical University; Institute of Experimental Medicine
Russian Federation
Russian Federation
Nikita A. Galankin.
2 Litovskaya Str., Saint Petersburg 194100; 12 Academician Pavlov Str., Saint Petersburg 197022
WoS ResearcherID KDP-1487-2024, Scopus Author ID 59906453700
O. A. Gromova
Federal Research Center “Computer Science and Control”, Russian Academy of Sciences
Russian Federation
Russian Federation
Olga A. Gromova - Dr. Sci. Med., Prof.
44 corp. 2 Vavilov Str., Moscow 119333
WoS ResearcherID J-4946-2017, Scopus Author ID 7003589812
I. S. Sardaryan
Saint Petersburg Pediatric Medical University
Russian Federation
Russian Federation
Ivan S. Sardaryan - PhD, Assoc. Prof.
2 Litovskaya Str., Saint Petersburg 194100
Scopus Author ID 57200672112
References
1. Clavenna A., Bonati M. Adverse drug reactions in childhood: a review of prospective studies and safety alerts. Arch Dis Child. 2009; 94 (9): 724–8. https://doi.org/10.1136/adc.2008.154377.
2. Perucca P., Carter J., Vahle V., Gilliam F.G. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology. 2009; 72 (14): 1223–9. https://doi.org/10.1212/01.wnl.0000345667.45642.61.
3. Giussani G., Bianchi E., Canelli V., et al. Antiepileptic drug discontinuation by people with epilepsy in the general population. Epilepsia. 2017; 58 (9): 1524–32. https://doi.org/10.1111/epi.13853.
4. Perucca P., Gilliam F.G. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012; 11 (9): 792–802. https://doi.org/10.1016/S1474-4422(12)70153-9.
5. Tadtaeva Z.G., Galustyan A.N., Gromova O.A., et al. Pharmacotherapy of epilepsy: a brief reference guide. Moscow: GEOTAR-Media; 2023: 94 pp. (in Russ.).
6. Egunsola O., Choonara I., Sammons H.M. Safety of levetiracetam in paediatrics: a systematic review. PLoS One. 2016; 11 (3): e0149686. https://doi.org/10.1371/journal.pone.0149686.
7. de Toledo M., de la Fuente E., Ramos C., et al. Extensive pharmacokinetic variability of levetiracetam. Are doctors aware? Epilepsy Res. 2022; 187: 107029. https://doi.org/10.1016/j.eplepsyres.2022.107029.
8. Kuyucu S., Caubet J.C. Hypersensitivity reactions to antiepileptic drugs in children: epidemiologic, pathogenetic, clinical, and diagnostic aspects. J Allergy Clin Immunol Pract. 2018; 6 (6): 1879–891.e1. https://doi.org/10.1016/j.jaip.2018.07.003.
9. Zhao W., Meng H. Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population. Bioengineered. 2022; 13 (3): 7709–45. https://doi.org/10.1080/21655979.2022.2036916.
10. Galankin N.A., Tadtaeva Z.G., Sardaryan I.S., et al. Impact of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms on antiepileptic drug safety and efficacy. Epilepsia i paroksizmal'nye sostoania / Epilepsy and Paroxysmal Conditions. 2025; 17 (1): 70–81 (in Russ.). https://doi.org/10.17749/2077-8333/epi.par.con.2025.240.
11. Li S., Cao J., Xiao N., Cai F. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy. J Child Neurol. 2010; 25 (5): 609–13. https://doi.org/10.1177/0883073809342489.
12. Incecik F., Hergüner M.O., Altunbasak S. The efficacy and side effects of levetiracetam on refractory epilepsy in children. J Pediatr Neurosci. 2012; 7 (1): 19–22. https://doi.org/10.4103/1817-1745.97614.
13. Zhao T., Yu J., Wang T.T., et al. Impact of ABCB1 polymorphism on levetiracetam serum concentrations in epileptic uygur children in china. Ther Drug Monit. 2020; 42 (6): 886–92. https://doi.org/10.1097/FTD.0000000000000805.
14. Tadtaeva Z.G., Galustyan A.N., Gromova O.A., Sardaryan I.S. Third generation antiepileptic drugs: mechanism of action, pharmacokinetics, interaction and use in childhood. Epilepsia i paroksizmal'nye sostoania / Epilepsy and Paroxysmal Conditions. 2023; 15 (2): 160–70 (in Russ.). https://doi.org/10.17749/2077-8333/epi.par.con.2023.149.
15. Karlov V.А. Epilepsy in children and adult women and men. A guide for doctors. 2nd ed. Мoscow: Binom; 2019: 896 pp. (in Russ.).
16. Fomina M.Yu., Melashenko T.V. Epileptic encephalopathies and developmental encephalopathies of infancy. Clinical observations. The experience of the Perinatal Center of St. Petersburg State Pediatric Medical University. Pediatrician (St. Petersburg). 2025; 16 (2): 105–19 (in Russ.). https://doi.org/10.56871/PED.2025.40.67.010.
17. Farooq M.U., Bhatt A., Majid A., et al. Levetiracetam for managing neurologic and psychiatric disorders. Am J Health Syst Pharm. 2009; 66 (6): 541–61. https://doi.org/10.2146/ajhp070607.
18. Karlov V.A., Kozhokaru A.B., Vlasov P.N., et al. Efficacy assessment of levetiracetam monotherapy in newly-diagnosed epilepsy in adults using epileptiform activity index. Epilepsia i paroksizmal'nye sostoania / Epilepsy and Paroxysmal Conditions. 2020; 12 (2): 93–104 (in Russ.) https://doi.org/10.17749/2077-8333/epi.par.con.2020.024.
19. Cortes-Altamirano J.L., Olmos-Hernández A., Bonilla-Jaime H., et al. Levetiracetam as an antiepileptic, neuroprotective, and hyperalgesic drug. Neurol India. 2016; 64 (6): 1266–75. https://doi.org/10.4103/0028-3886.193801.
20. Pellock J.M., Glauser T.A., Bebin E.M., et al. Pharmacokinetic study of levetiracetam in children. Epilepsia. 2001; 42 (12): 1574–9. https://doi.org/10.1046/j.1528-1157.2001.41300.x.
21. Baxter K. Stockley’s drug interactions: a source book of interactions, their mechanisms, clinical importance and management. 9th ed. Pharmaceutical Press; 2010: 1792 pp.
22. Mbizvo G.K., Dixon P., Hutton J.L., Marson A.G. The adverse effects profile of levetiracetam in epilepsy: a more detailed look. Int J Neurosci. 2014; 124 (9): 627–34. https://doi.org/10.3109/00207454.2013.866951.
23. Wyllie E. (Ed.) Wyllie’s treatment of epilepsy: principles and practice. 7th ed. Lippincott Williams & Wilkins; 2021: 1096 pp.
24. Howard P., Remi J., Remi C., et al. Levetiracetam. J Pain Symptom Manage. 2018; 56 (4): 645–9. https://doi.org/10.1016/j.jpainsymman.2018.07.012.
25. Hansen C.C., Ljung H., Brodtkorb E., Reimers A. Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel. Behav Neurol. 2018; 2018: 2064027. https://doi.org/10.1155/2018/2064027.
26. Mula M., Sander J.W. Suicidal ideation in epilepsy and levetiracetam therapy. Epilepsy Behav. 2007; 11 (1): 130–2. https://doi.org/10.1016/j.yebeh.2007.04.008.
27. Esang M., Santos M.G., Ahmed S. Levetiracetam and suicidality: a case report and literature review. Prim Care Companion CNS Disord. 2020; 22 (4): 19nr02502. https://doi.org/10.4088/PCC.19nr02502.
28. Tao K., Chen H., Chen Y., et al. Levetiracetam induces severe psychiatric symptoms in people with epilepsy. Seizure. 2024; 116: 147–50. https://doi.org/10.1016/j.seizure.2022.12.002.
29. Erdogan S., Bosnak M. Hallucination: a rare complication of levetiracetam theraphy. North Clin Istanb. 2017; 4 (3): 267–9. https://doi.org/10.14744/nci.2017.44366.
30. Shakya D.R., Dutta A., Gautam R. Hallucination in a seizure patient using levetiracetam: a case report. Case Report Med. 2012; 2012: 706243. https://doi.org/10.1155/2012/706243.
31. Tahir H., Ayyaz F., Ekwegh U. Visual and auditory hallucinations: an uncommon side effect of levetiracetam in an elderly patient. Cureus. 2022; 14 (10): e30668. https://doi.org/10.7759/cureus.30668.
32. Camacho A., Espín J.C., Nuñez N., Simón R. Levetiracetam-induced reversible autistic regression. Pediatr Neurol. 2012; 47 (1): 65–7. https://doi.org/10.1016/j.pediatrneurol.2012.04.002.
33. Zhou D.J., Pavuluri S., Snehal I., et al. Movement disorders associated with antiseizure medications: a systematic review. Epilepsy Behav. 2022; 131 (Pt A): 108693. https://doi.org/10.1016/j.yebeh.2022.108693.
34. Yim S.H., Choi Y.H., Heo K., Cho K.H. A case of dyskinesia after levetiracetam administration. BMC Neurol. 2019; 19 (1): 292. https://doi.org/10.1186/s12883-019-1519-8.
35. Le V., Surineni K., Elias G. A case of partially reversible oral-buccal-lingual dyskinesia after prolonged levetiracetam exposure. Am J Geriatr Psychiatry. 2024; 32 (4): S106. https://doi.org/10.1016/j.jagp.2024.01.190.
36. Lee J.S., Woo H.G., Hwang K.J. Tongue tremor after levetiracetam administration. J Clin Neurol. 2021; 17 (4): 588–9. https://doi.org/10.3988/jcn.2021.17.4.588.
37. Surineni K., Le V., Jones D. A case of oral-buccal-lingual dyskinesia and neuropsychiatric symptoms after prolonged levetiracetam exposure. Cureus. 2024; 16 (6): e62692. https://doi.org/10.7759/cureus.62692.
38. Badarny S., Badarny Y., Mihilia F. Republished: Unusual side effects of levetiracetam. Drug Ther Bull. 2023; 61 (2): 30–1. https://doi.org/10.1136/dtb.2022.242496rep.
39. Falhammar H., Lindh J.D., Calissendorff J., et al. Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: a population-based case-control study. Seizure. 2018; 59: 28–33. https://doi.org/10.1016/j.seizure.2018.04.025.
40. Nasrallah K., Silver B. Hyponatremia associated with repeated use of levetiracetam. Epilepsia. 2005; 46 (6): 972–3. https://doi.org/10.1111/j.1528-1167.2005.64004.x.
41. Rosca E.C., Simu M. Levetiracetam-induced hyponatremia. Acta Neurol Belg. 2018; 118 (1): 123–4. https://doi.org/10.1007/s13760-017-0825-4.
42. Belcastro V., Costa C., Striano P. Levetiracetam-associated hyponatremia. Seizure. 2008; 17 (4): 389–90. https://doi.org/10.1016/j.seizure.2007.10.007.
43. Nägele H., Rosenkranz M., Nägele M.P. Hyponatremia-induced epileptic seizure provoked by levetiracetam and pain medication intake in a patient with central diabetes insipidus. Case Rep Neurol. 2024; 16 (1): 204–7. https://doi.org/10.1159/000540320.
44. Gattu A.K., Murthy J.M.K. Recurrent hyponatremia: levetiracetam – an uncommon cause. Ann Indian Acad Neurol. 2023; 26 (3): 302–4. https://doi.org/10.4103/aian.aian_996_22.
45. Coughlin P., Patel G., Vadaketh J., Pandit R. A rare case of levetiracetam-induced refractory hypokalemia. Cureus. 2022; 14 (4): e23817. https://doi.org/10.7759/cureus.23817.
46. Aksoy D., Cevik B., Kurt S., et al. Hypokalemia and hypomagnesaemia related to levetiracetam use. J Clin Neurosci. 2014; 21 (11): 1989–90. https://doi.org/10.1016/j.jocn.2014.03.013.
47. Vallianou N.G., Geladari E., Chroni P., Kokkinakis E. Levetiracetam-associated hypokalemia and hypomagnesaemia among two patients treated for seizures. CNS Neurosci Ther. 2015; 21 (6): 539. https://doi.org/10.1111/cns.12398.
48. Ammad Ud Din M., Ather Hussain S., Bodrog A. delayed recognition of levetiracetam-induced pancytopenia. Eur J Case Rep Intern Med. 2021; 8 (3): 002449. https://doi.org/10.12890/2021_002449.
49. Unkun R., Kizilkilic E.K., Delil S., et al. Levetiracetam-associated pancytopenia. Acta Neurol Belg. 2023; 123 (4): 1625–6. https://doi.org/10.1007/s13760-022-02138-1.
50. Jain R.S., Srivastava T., Sharma P., Pemawat A. Levetiracetam-mediated drug-induced liver injury – a rare presentation and review of literature. Ann Indian Acad Neurol. 2024; 27 (1): 87–90. https://doi.org/10.4103/aian.aian_730_23.
51. Moinuddin I.A. Suspected levetiracetam-induced rhabdomyolysis: a case report and literature review. Am J Case Rep. 2020; 21: e926064. https://doi.org/10.12659/AJCR.926064.
52. Lyles S., Atalay R.T., Taylor S., et al. Weighing the risk of seizure control: a case of levetiracetam-induced rhabdomyolysis. Cureus. 2024; 16 (11): e74111. https://doi.org/10.7759/cureus.74111.
53. Kodama K., Imai T., Kuwana T., et al. Two cases of levetiracetam-induced rhabdomyolysis with low levetiracetam blood concentrations. Cureus. 2025; 17 (3): e80877. https://doi.org/10.7759/cureus.80877.
54. Kazmi J.S., Albarghouthy N., Ramsaywak R. Levetiracetam-induced rhabdomyolysis reversed by discontinuation: a case report. Cureus. 2023; 15 (11): e48955. https://doi.org/10.7759/cureus.48955.
55. Romero K.N., O’Brien M.C., Agrawal A., Hasan I. Creatine kinase surge: levetiracetam-induced rhabdomyolysis. Cureus. 2024; 16 (8): e66715. https://doi.org/10.7759/cureus.66715.
56. Qureshi M., Abraham P.A., Al-Faras A., et al. Rhabdomyolysis induced by levetiracetam: a case report in kuwait. Case Rep Neurol Med. 2024; 2024: 1234738. https://doi.org/10.1155/2024/1234738.
57. Algahtani H., Marghalani S., Satti M., Shirah B. Levetiracetam-induced skin hyperpigmentation: an extremely rare undesirable side effect. J Epilepsy Res. 2017; 7 (2): 106–8. https://doi.org/10.14581/jer.17016.
58. Rashid M., Rajan A.K., Chhabra M., Kashyap A. Levetiracetam and cutaneous adverse reactions: a systematic review of descriptive studies. Seizure. 2020; 75: 101–9. https://doi.org/10.1016/j.seizure.2020.01.002.
59. Lim J.A., Jamil A., Ramli N.A., et al. Severe cutaneous adverse reaction to drug excipient following brand-to-generic switch of levetiracetam. Am J Health Syst Pharm. 2024; 81 (3): e69–72. https://doi.org/10.1093/ajhp/zxad264.
60. Kahraman Ş., Değermenci Ş., Oktay M.A., et al. Anaphylaxis to levetiracetam in an adolescent: a very rare occurence. Turk J Pediatr. 2021; 63 (3): 506–9. https://doi.org/10.24953/turkjped.2021.03.019.
61. Alkhotani A., McLachlan R.S. Levetiracetam induced angioedema in a patient with previous anticonvulsant hypersensitivity reaction to phenytoin and lamotrigine. Seizure. 2012; 21 (5): 407–8. https://doi.org/10.1016/j.seizure.2012.03.007.
62. Koklu E., Ariguloglu E.A., Koklu S. Levetiracetam-induced anaphylaxis in a neonate. Pediatr Neurol. 2014; 50 (2): 192–4. https://doi.org/10.1016/j.pediatrneurol.2013.09.006.
63. Callenbach P.M.C., Arts W.F.M., ten Houten R., et al. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study. Eur J Paediatr Neurol. 2008; 12 (4): 321–7. https://doi.org/10.1016/j.ejpn.2007.09.004.
64. Delanty N., Jones J., Tonner F. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. Epilepsia. 2012; 53 (1): 111–9. https://doi.org/10.1111/j.1528-1167.2011.03300.x.
65. Mula M., Trimble M.R., Sander J.W.A.S. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure. 2004; 13 (1): 55–7. https://doi.org/10.1016/S1059-1311(03)00111-0.
66. White J.R., Walczak T.S., Leppik I.E., et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology. 2003; 61 (9): 1218–21. https://doi.org/10.1212/01.wnl.0000091865.46063.67.
67. Helmstaedter C., Mihov Y., Toliat M.R., et al. Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. Epilepsia. 2013; 54 (1): 36–44. https://doi.org/10.1111/j.1528-1167.2012.03603.x.
68. Campbell C., McCormack M., Patel S., et al. A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam. Epilepsia. 2022; 63 (6): 1563–70. https://doi.org/10.1111/epi.17228.
69. Doumiati H., Ezzeddine A. Dyskinesia after levetiracetam therapy: a case report. Res Sq. Published online May 7, 2024. https://doi.org/10.21203/rs.3.rs-4343478/v1.
70. Zykov V.P., Kashirina E.A., Naugolnykh Yu.V. Possibilities of tic hyperkinesia therapy using antiсonvulsants. Epilepsia i paroksizmal'nye sostoania / Epilepsy and Paroxysmal Conditions. 2016; 8 (3): 45–51 (in Russ.). https://doi.org/10.17749/2077-8333.2016.8.3.045-051.
71. Vles G.F., Hendriksen J.G., Visschers A., et al. Levetiracetam therapy for treatment of choreoathetosis in dyskinetic cerebral palsy. Dev Med Child Neurol. 2009; 51 (6): 487–90. https://doi.org/10.1111/j.1469-8749.2008.03170.x.
72. Lu X., Wang X. Hyponatremia induced by antiepileptic drugs in patients with epilepsy. Expert Opin Drug Saf. 2017; 16 (1): 77–87. https://doi.org/10.1080/14740338.2017.1248399.
73. Durá-Travé T., Gallinas-Victoriano F., Malumbres-Chacón M., et al. Vitamin D deficiency in children with epilepsy taking valproate and levetiracetam as monotherapy. Epilepsy Res. 2018; 139: 80–4. https://doi.org/10.1016/j.eplepsyres.2017.11.013.
74. Maher Zidan A., Abd El Azim Abd El Aziz S., Ahmed El-Serogy H., Mohammed El-Sawy D. Effects of levetiracetam monotherapy on vitamin D status and serum calcium in children with epilepsy. Asian J Pediatr Res. Published online February 6, 2023. https://doi.org/10.9734/ajpr/2023/v11i1212.
75. Jiang X., Xiong F., Wu S., et al. Effects of levetiracetam on bone mineral density and bone metabolism in patients with epilepsy: a systematic review and meta-analysis. Epilepsy Behav. 2024; 158: 109925. https://doi.org/10.1016/j.yebeh.2024.109925.
76. Aksoy D., Güveli B.T., Ak P.D., et al. Effects of oxcarbazepine and levetiracetam on calcium, ionized calcium, and 25-OH vitamin-D3 levels in patients with epilepsy. Clin Psychopharmacol Neurosci. 2016; 14 (1): 74–8. https://doi.org/10.9758/cpn.2016.14.1.74.
77. Attilakos A., Tsirouda M., Dinopoulos A., et al. Vitamin D status in children with epilepsy treated with levetiracetam monotherapy. Epilepsy Res. 2018; 148: 116. https://doi.org/10.1016/j.eplepsyres.2018.09.003.
78. Saket S., Varasteh N., Halimi Asl A.A., Saneifard H. How antiepileptics may change the serum level of vitamin D, calcium, and phosphorus in children with epilepsy. Iran J Child Neurol. 2021; 15 (1): 19–27. https://doi.org/10.22037/ijcn.v15i1.25952.
79. Sahaya K., Goyal M.K., Sarwal A., Singh N.N. Levetiracetam-induced thrombocytopenia among inpatients: a retrospective study. Epilepsia. 2010; 51 (12): 2492–5. https://doi.org/10.1111/j.1528-1167.2010.02788.x.
80. Ucar H.K., Sarigecili E., Bilen S., Sari S. Short-term and long-term effects of levetiracetam monotherapy on hematological parameters in children with idiopathic epilepsy. Sisli Etfal Hastan Tip Bul. 2023; 57 (1): 46–53. https://doi.org/10.14744/SEMB.2022.98523.
81. Vidaurre J., Gedela S., Yarosz S. Antiepileptic drugs and liver disease. Pediatr Neurol. 2017; 77: 23–36. https://doi.org/10.1016/j.pediatrneurol.2017.09.013.
82. Tan T.C.H., de Boer B.W., Mitchell A., et al. Levetiracetam as a possible cause of fulminant liver failure. Neurology. 2008; 71 (9): 685–6. https://doi.org/10.1212/01.wnl.0000324604.11657.c6.
83. Rogalewski A., Zuhorn F., Wilkens L., et al. Severe drug-induced liver injury caused by levetiracetam – a case report and review of the literature. Epilepsy Behav Rep. 2021; 16: 100464. https://doi.org/10.1016/j.ebr.2021.100464.
84. Kashiura M., Sugiyama K., Hamabe Y. Association between rapid serum sodium correction and rhabdomyolysis in water intoxication: a retrospective cohort study. J Intensive Care. 2017; 5: 37. https://doi.org/10.1186/s40560-017-0233-0.
85. Rastogi V., Singh D., Kaur B., et al. Rhabdomyolysis: a rare adverse effect of levetiracetam. Cureus. 2018; 10 (5): e2705. https://doi.org/10.7759/cureus.2705.
86. Jones R.T., Evans W., Mersfelder TL., Kavanaugh K. Rare red rashes: a case report of levetiracetam-induced cutaneous reaction and review of the literature. Am J Ther. 2016; 23 (3): e944–6. https://doi.org/10.1097/MJT.0000000000000105.
87. Kim H.K., Kim D.Y., Bae E.K., Kim D.W. Adverse skin reactions with antiepileptic drugs using Korea adverse event reporting system database, 2008–2017. J Korean Med Sci. 2020; 35 (4): e17. https://doi.org/10.3346/jkms.2020.35.e17.
88. Melashenko T.V., Palchik A.B. Fetal valproate syndrome (review and case report). Pediatrician (St. Petersburg). 2023; 14 (2): 117–25. https://doi.org/10.17816/PED142117-125.
89. Tural S., Tekcan A., Elbistan M., et al. Genotoxic effects of prenatal exposure to levetiracetam during pregnancy on rat offsprings. In Vivo. 2015; 29 (1): 77–81.
90. French J., Edrich P., Cramer J.A. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res. 2001; 47 (1-2): 77–90. https://doi.org/10.1016/s0920-1211(01)00296-0.
91. He Z., Liu C., Lin L., et al. Real-world safety of levetiracetam: mining and analysis of its adverse drug reactions based on FAERS database. Seizure. 2024; 117: 253–60. https://doi.org/10.1016/j.seizure.2024.03.009.
Review
For citations:
Melashenko T.V., Tadtaeva Z.G., Galustyan A.N., Galankin N.A., Gromova O.A., Sardaryan I.S. Rare levetiracetam-related adverse events in treatment of epilepsy. Epilepsy and paroxysmal conditions. 2026;18(1):38-47. (In Russ.) https://doi.org/10.17749/2077-8333/epi.par.con.2026.258
Views:
833
JATS XML
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 